Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

Summary

To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.

Timeline

Start

2007-11

Primary completion

2009-01

Completion

2009-01

Outcome

Met primary endpoint

registry analysis (superiority or other test); Placebo vs Fesoterodine 4 mg; p = 0.002; Mean Difference (Final Values) -0.34 (95% CI -0.56 to -0.13); ANCOVA NCT00561951 ↗

registry analysis (superiority or other test); Placebo vs Fesoterodine 8 mg; p <0.001; Mean Difference (Final Values) -0.39 (95% CI -0.60 to -0.17); ANCOVA NCT00561951 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fesoterodine	Other / unclassified	4 mg	Oral
Subject	Fesoterodine	Other / unclassified	8 mg	Oral

Indications